Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Authors
Keywords
-
Journal
Nature Communications
Volume 8, Issue -, Pages 16078
Publisher
Springer Nature
Online
2017-07-17
DOI
10.1038/ncomms16078
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells
- (2015) Haiming Dai et al. GENES & DEVELOPMENT
- Origins, genetic landscape, and emerging therapies of small cell lung cancer
- (2015) Ekaterina A. Semenova et al. GENES & DEVELOPMENT
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer
- (2015) Anthony C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
- (2014) Camilla L. Christensen et al. CANCER CELL
- Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer
- (2014) E. E. Gardner et al. CANCER RESEARCH
- CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
- (2014) Chun-Hao Huang et al. GENES & DEVELOPMENT
- Targeting BCL2 for the Treatment of Lymphoid Malignancies
- (2014) Mary Ann Anderson et al. SEMINARS IN HEMATOLOGY
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency
- (2012) Guo Wei et al. CANCER CELL
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- The RNA polymerase II CTD coordinates transcription and RNA processing
- (2012) J.-P. Hsin et al. GENES & DEVELOPMENT
- Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
- (2012) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
- (2012) W. W. Lockwood et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells
- (2011) A. A. Morales et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia
- (2011) Loren D. Walensky JOURNAL OF CLINICAL ONCOLOGY
- Novel strategies for the treatment of small-cell lung carcinoma
- (2011) William N. William et al. Nature Reviews Clinical Oncology
- Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing
- (2010) Maria Gabriella Brasca et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program
- (2010) D. Ren et al. SCIENCE
- Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1
- (2009) S. Chen et al. MOLECULAR AND CELLULAR BIOLOGY
- Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial Apoptosis
- (2009) Hyungjin Kim et al. MOLECULAR CELL
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
- (2008) A. R. Shoemaker et al. CLINICAL CANCER RESEARCH
- To Trigger Apoptosis, Bak Exposes Its BH3 Domain and Homodimerizes via BH3:Groove Interactions
- (2008) Grant Dewson et al. MOLECULAR CELL
- Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
- (2008) S WANG et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started